Liothyronine

(asked on 24th July 2018) - View Source

Question to the Department of Health and Social Care:

To ask Her Majesty's Government what assessment they have made of whether the advice provided by PresQIPP to Clinical Commissioning Groups is consistent with national guidelines on the prescription of Liothryonine (T3) to NHS patients.


Answered by
Lord O'Shaughnessy Portrait
Lord O'Shaughnessy
This question was answered on 26th July 2018

We have not made any assessment on the accuracy and advice provided by PrescQIPP. Nor have we made any assessment on whether the advice provided by PrescQIPP to clinical commissioning groups (CCGs) is consistent with national guidelines on the prescription of liothyronine to National Health Service patients. We can confirm that we have not received any assurances from PrescQIPP on whether or not it has taken patient stakeholder views into account as it is the responsibility of CCGs to seek any such assurances.

PrescQIPP is an independent social enterprise and it is for CCGs to decide whether and how they take that guidance into account when making decisions. However, NHS England expects CCGs to have due regard to the guidance Items which should not routinely be prescribed in primary care: Guidance for CCGs, published in November 2017 by NHS England and NHS Clinical Commissioners when considering the prescribing of liothyronine. A copy of the guidance is attached.

Reticulating Splines